Encompass Health Co. (NYSE:EHC – Get Rating) Director Kevin J. O’connor acquired 1,000 shares of the company’s stock in a transaction that occurred on Friday, May 6th. The shares were acquired at an average cost of $66.48 per share, for a total transaction of $66,480.00. Following the acquisition, the director now directly owns 3,436 shares of the company’s stock, valued at $228,425.28. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Encompass Health stock opened at $63.66 on Tuesday. The stock has a market cap of $6.33 billion, a PE ratio of 16.28, a P/E/G ratio of 2.18 and a beta of 0.95. The stock has a 50-day moving average price of $69.31 and a 200 day moving average price of $66.08. Encompass Health Co. has a 52 week low of $56.31 and a 52 week high of $88.58. The company has a current ratio of 1.26, a quick ratio of 1.23 and a debt-to-equity ratio of 1.32.
Encompass Health (NYSE:EHC – Get Rating) last posted its quarterly earnings data on Wednesday, April 27th. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Encompass Health had a return on equity of 17.99% and a net margin of 7.51%. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.05 EPS. On average, equities analysts predict that Encompass Health Co. will post 4.11 EPS for the current year.
A number of research analysts recently weighed in on EHC shares. Truist Financial upped their price objective on Encompass Health from $78.00 to $85.00 in a report on Thursday, April 7th. Zacks Investment Research raised Encompass Health from a “sell” rating to a “hold” rating and set a $76.00 target price on the stock in a report on Monday, April 11th. Deutsche Bank Aktiengesellschaft lowered their target price on Encompass Health from $95.00 to $80.00 in a report on Thursday, January 20th. Raymond James lowered their target price on Encompass Health from $90.00 to $80.00 and set a “strong-buy” rating on the stock in a report on Monday, February 7th. Finally, Credit Suisse Group lowered their target price on Encompass Health from $84.00 to $77.00 in a report on Thursday, February 3rd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $83.89.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quadrature Capital Ltd lifted its holdings in shares of Encompass Health by 12.9% during the 3rd quarter. Quadrature Capital Ltd now owns 15,105 shares of the company’s stock worth $1,134,000 after acquiring an additional 1,725 shares during the period. Clark Capital Management Group Inc. purchased a new position in shares of Encompass Health during the 3rd quarter worth about $2,511,000. Gyon Technologies Capital Management LP purchased a new position in shares of Encompass Health during the 3rd quarter worth about $362,000. Jump Financial LLC purchased a new position in shares of Encompass Health during the 3rd quarter worth about $452,000. Finally, Yousif Capital Management LLC purchased a new stake in shares of Encompass Health during the 4th quarter worth about $3,543,000. 91.70% of the stock is owned by institutional investors.
About Encompass Health (Get Rating)
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
- Get a free copy of the StockNews.com research report on Encompass Health (EHC)
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Johnson Outdoors Falls On Bleak Outlook
- Institutional Support For Tyson Foods Is Growing
- Time to Buy These 3 Oversold Mid-Caps
- Littelfuse Stock is Hitting on All Cylinders
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.